{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T22:28:24Z","timestamp":1775341704724,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Veratstem Inc"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA210084"],"award-info":[{"award-number":["R35 CA210084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI Research Specialist","award":["R50 CA211466"],"award-info":[{"award-number":["R50 CA211466"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite improvements in prevention and treatment, severe coronavirus disease 2019 (COVID-19) is associated with high mortality. Phosphoinositide 3-kinase (PI3K) pathways contribute to cytokine and cell-mediated lung inflammation. We conducted a randomized, placebo-controlled, double-blind pilot trial to determine the feasibility, safety, and preliminary activity of duvelisib, a PI3K\u03b4\u03b3 inhibitor, for the treatment of COVID-19 critical illness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We enrolled adults aged \u226518 years with a primary diagnosis of COVID-19 with hypoxic respiratory failure, shock, and\/or new cardiac disease, without improvement after at least 48 hours of corticosteroid. Participants received duvelisib (25\u2005mg) or placebo for up to 10 days. Participants had daily semi-quantitative viral load measurements performed. Dose modifications were protocol driven due to adverse events (AEs) or logarithmic change in viral load. The primary endpoint was 28-day overall survival (OS). Secondary endpoints included hospital and intensive care unit length of stay, 60-day OS, and duration of critical care interventions. Safety endpoints included viral kinetics and AEs. Exploratory endpoints included serial cytokine measurements and cytometric analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifteen patients were treated in the duvelisib cohort, and 13 in the placebo cohort. OS at 28 days was 67% (95% confidence interval [CI], 38%\u201388%) compared to 62% (95% CI, 32%\u201386%) for placebo (P = .544). Sixty-day OS was 60% versus 46%, respectively (hazard ratio, 0.66 [95% CI, .22\u20131.96]; P = .454). Other secondary outcomes were comparable. Duvelisib was associated with lower inflammatory cytokines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this pilot study, duvelisib did not significantly improve 28-day OS compared to placebo for severe COVID-19. Duvelisib appeared safe in this critically ill population and was associated with reduction in cytokines implicated in COVID-19 and acute respiratory distress syndrome, supporting further investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT04372602.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad518","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T18:48:12Z","timestamp":1698432492000},"source":"Crossref","is-referenced-by-count":4,"title":["Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-2418","authenticated-orcid":false,"given":"Scott R","family":"Goldsmith","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"},{"name":"City of Hope National Medical Center , Duarte, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahrettin","family":"Covut","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5023","authenticated-orcid":false,"given":"Mark","family":"Fiala","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifu","family":"Xiang","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahid","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Department of Anesthesiology, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"},{"name":"Department of Anesthesiology, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Moore","sequence":"additional","affiliation":[{"name":"Barnes Jewish Christian Medical Group, Missouri Baptist Hospital , St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Bradtke","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Christen","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P","family":"Rettig","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Christ","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Gehrs","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Street","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Wallace","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Ritchey","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Pachter","sequence":"additional","affiliation":[{"name":"Verastem Oncology , Needham, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijal","family":"Parikh","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik R","family":"Dubberke","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F","family":"DiPersio","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis , St Louis, Missouri , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"2023113021410616200_ofad518-B1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41581-022-00642-4","article-title":"Therapeutic advances in COVID-19","volume":"19","author":"Murakami","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2023113021410616200_ofad518-B2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/jama.2020.3633","article-title":"Care for critically ill patients with COVID-19","volume":"323","author":"Murthy","year":"2020","journal-title":"JAMA"},{"key":"2023113021410616200_ofad518-B3","author":"Bhimraj"},{"key":"2023113021410616200_ofad518-B4","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"2023113021410616200_ofad518-B5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.15585\/mmwr.mm7037e1","article-title":"Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status\u201413 U.S. jurisdictions, April 4\u2013July 17, 2021","volume":"70","author":"Scobie","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023113021410616200_ofad518-B6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.15585\/mmwr.mm7104e2","article-title":"COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence\u201425 U.S. jurisdictions, April 4\u2013December 25, 2021","volume":"71","author":"Johnson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023113021410616200_ofad518-B7","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","article-title":"COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network","volume":"8","author":"Ludwig","year":"2021","journal-title":"Lancet Haematol"},{"key":"2023113021410616200_ofad518-B8","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2665-9913(22)00102-3","article-title":"Breakthrough SARS-CoV-2 infections with the Delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies","volume":"4","author":"Boekel","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023113021410616200_ofad518-B9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"2023113021410616200_ofad518-B10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"2023113021410616200_ofad518-B11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023113021410616200_ofad518-B12","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"2023113021410616200_ofad518-B13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"2023113021410616200_ofad518-B14","doi-asserted-by":"crossref","first-page":"101489","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2023113021410616200_ofad518-B15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci Immunol"},{"key":"2023113021410616200_ofad518-B16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543784.2017.1312338","article-title":"Duvelisib: a phosphoinositide-3 kinase \u03b4\/\u03b3 inhibitor for chronic lymphocytic leukemia","volume":"26","author":"Vangapandu","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"2023113021410616200_ofad518-B17","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"2023113021410616200_ofad518-B18","doi-asserted-by":"crossref","first-page":"e94496","DOI":"10.1371\/journal.pone.0094496","article-title":"Identification of a role for the PI3K\/AKT\/mTOR signaling pathway in innate immune cells","volume":"9","author":"Xie","year":"2014","journal-title":"PLoS One"},{"key":"2023113021410616200_ofad518-B19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","article-title":"COVID-19 infection: an overview on cytokine storm and related interventions","volume":"19","author":"Montazersaheb","year":"2022","journal-title":"Virol J"},{"key":"2023113021410616200_ofad518-B20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4049\/jimmunol.1402513","article-title":"The acute respiratory distress syndrome: from mechanism to translation","volume":"194","author":"Han","year":"2015","journal-title":"J Immunol"},{"key":"2023113021410616200_ofad518-B21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/biomedicines10040756","article-title":"PI3K signaling in mechanisms and treatments of pulmonary fibrosis following sepsis and acute lung injury","volume":"10","author":"Margaria","year":"2022","journal-title":"Biomedicines"},{"key":"2023113021410616200_ofad518-B22","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"},{"key":"2023113021410616200_ofad518-B23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/B978-0-12-396456-4.00002-X","article-title":"Hijakt: the PI3K\/Akt pathway in virus replication and pathogenesis","volume":"106","author":"Dunn","year":"2012","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1\u20132","key":"2023113021410616200_ofad518-B24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbadis.2005.04.004","article-title":"JNK And PI3k\/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells","volume":"1741","author":"Mizutani","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"2023113021410616200_ofad518-B25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fimmu.2020.00432","article-title":"Inhibition of PI3K\u03b4 enhances poly I:C-induced antiviral responses and inhibits replication of human metapneumovirus in murine lungs and human bronchial epithelial cells","volume":"11","author":"Fujita","year":"2020","journal-title":"Front Immunol"},{"key":"2023113021410616200_ofad518-B26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.03659-14","article-title":"Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis","volume":"59","author":"Kindrachuk","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023113021410616200_ofad518-B27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/1535-7163.MCT-11-0850","article-title":"JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells","volume":"11","author":"Yamada","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2023113021410616200_ofad518-B28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2023113021410616200_ofad518-B29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","article-title":"Severe cytokine-release syndrome after T cell\u2013replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti\u2013IL-6 therapy is safe and well tolerated","volume":"22","author":"Abboud","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023113021410616200_ofad518-B30","doi-asserted-by":"crossref","first-page":"106713","DOI":"10.1016\/j.leukres.2021.106713","article-title":"Combination of dociparstat sodium (DSTAT), a CXCL12\/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS","volume":"110","author":"Huselton","year":"2021","journal-title":"Leuk Res"},{"key":"2023113021410616200_ofad518-B31","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/v13061062","article-title":"The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner","volume":"13","author":"Callahan","year":"2021","journal-title":"Viruses"},{"key":"2023113021410616200_ofad518-B32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"2023113021410616200_ofad518-B33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/thoraxjnl-2016-208597","article-title":"Evidence for chemokine synergy during neutrophil migration in ARDS","volume":"72","author":"Williams","year":"2017","journal-title":"Thorax"},{"key":"2023113021410616200_ofad518-B34","doi-asserted-by":"crossref","first-page":"808797","DOI":"10.3389\/fphar.2021.808797","article-title":"The role of interleukin-8 in lung inflammation and injury: implications for the management of COVID-19 and hyperinflammatory acute respiratory distress syndrome","volume":"12","author":"Cesta","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023113021410616200_ofad518-B35","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe4782","article-title":"Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2\u2013reactive CD8 + T cells","volume":"6","author":"Kusnadi","year":"2021","journal-title":"Sci Immunol"},{"key":"2023113021410616200_ofad518-B36","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41423-021-00750-4","article-title":"Activation or exhaustion of CD8+ T cells in patients with COVID-19","volume":"18","author":"Rha","year":"2021","journal-title":"Cell Mol Immunol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad518\/52635354\/ofad518.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/11\/ofad518\/53899070\/ofad518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/11\/ofad518\/53899070\/ofad518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T21:42:07Z","timestamp":1701380527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad518\/7331254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad518","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,10,27]]},"article-number":"ofad518"}}